Mastercard Inc current report, Q3 FY2010

Business Context and Reporting Period

Company: Mastercard Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2010
Event: Announcement of a recommended cash acquisition of DataCash Group plc by Mastercard/Europay U.K. Limited (MEPUK), an indirect wholly-owned subsidiary of Mastercard.

Key Financial Metrics

This filing is a current report regarding a corporate transaction and does not contain periodic financial statements (e.g., revenue, profit, cash flow, or margins) for the reporting period.

Metric Value
Acquisition Price per Share 360 pence (cash)
Total Aggregate Consideration Approximately £333 million
USD Equivalent Approximately $520 million

Material Changes

The primary material change is the initiation of the acquisition of DataCash Group plc. The transaction is structured as a court-sanctioned scheme of arrangement under English company law. As of the filing date, MEPUK has secured binding commitments from holders of approximately 52% of DataCash shares (including directors) to vote in favor of the deal.

Guidance, Outlook, and Risks

  • Expected Closing: The acquisition is expected to close by the end of October 2010.
  • Conditions Precedent: The deal is subject to various conditions, including approval by a majority in number representing not less than 75% in value of voting DataCash shareholders.
  • Management Commentary: Mastercard issued a press release and hosted a conference call on August 19, 2010, to discuss the acquisition. A presentation was provided as Exhibit 99.2.
  • Risks: The transaction is contingent upon shareholder approval thresholds and regulatory/court sanctions.

Investor Verification Checklist

  • Verify the final shareholder approval percentage for DataCash to ensure the 75% value threshold is met.
  • Confirm the actual closing date, as the current timeline is an estimate (end of October 2010).
  • Review the "Rule 2.5 Announcement" on the London Stock Exchange website for detailed terms.
  • Monitor for any regulatory approvals required in the U.K. or other jurisdictions.